A STUDY ON THE CHARACTERISTICS OF DEPRESSION IN PATIENTS WITH MYASTHENIA GRAVIS AT 103 MILITARY HOSPITAL
Main Article Content
Abstract
SUMMARY
A STUDY ON THE CHARACTERISTICS OF DEPRESSION IN PATIENTS WITH MYASTHENIA GRAVIS AT 103 MILITARY HOSPITAL
Objective: To characterize depression and analyze their association with selected clinical features in patients with myasthenia gravis (MG) at the 103 Military Hospital.Methods: A cross-sectional descriptive study was conducted on 83 MG patients treated at 103 Military Hospital from July 2024 to April 2025. MG was diagnosed according to the Japanese criteria (2022), and depression were identified based on the DSM-5 diagnostic criteria and the Beck Depression Inventory (BDI). Results: The prevalence of depression among MG patients was 45,78%, with mild to moderate depression being most common. The most frequently reported depressive symptoms were fatigue and loss of appetite. Depression was significantly associated with female gender, history of myasthenic crisis, greater disease severity, and higher doses of prednisolone. No significant differences were found between depressed and non-depressed patients in terms of age, age at disease onset, or history of thymectomy. Conclusion: Depression is a relatively common comorbidity in patients with myasthenia gravis. Disease severity, prior history of myasthenic crisis, female sex, and high-dose corticosteroid therapy are factors associated with depression in this population.
Article Details
Keywords
Myasthenia gravis, depression, 103 Military Hospital
References
2. Claytor B., Cho S. M., Li Y. (2023). Myasthenic crisis, Muscle Nerve, 68(1): 8-19.
3. Gavrilov Y. V., Alekseeva T. M., Kreis O. A., et al. (2020). Depression in myasthenia gravis: a heterogeneous and intriguing entity, J Neurol, 267(6): 1802-1811.
4. Kuehner C. (2017). Why is depression more common among women than among men?, Lancet Psychiatry, 4(2): 146-158.
5. Kulaksizoglu I. B. (2007). Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment, CNS Drugs, 21(6): 473-81.
6. Mihalache A., Vilciu C., Petrescu D., et al. (2024). Depression: A Contributing Factor to the Clinical Course in Myasthenia Gravis Patients, Medicina, 60(1): 56.
7. Salari N., Fatahi B., Bartina Y., et al. (2021). Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis, J Transl Med, 19(1): 516.
8. Suzuki Y., Utsugisawa K., Suzuki S., et al. (2011). Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study, BMJ Open, 1(2): e000313.